

9 December 2021

Diaceutics PLC
("Diaceutics" or "the Company")

Launch of Test Signal and multi-year subscription contracts

[Diaceutics PLC](#), (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce the launch of its real-time Test Signal service in the US. Test Signal alerts a pharma customer when a patient tests positive for a biomarker linked to the profile of therapeutic linked to the pharmaceutical company. This information can now be provided within days of the test result being recorded by laboratories linked to this new service. Test Signal allows the opportunity for real time identification of patients eligible for treatment and follow up by the pharmaceutical company's marketing organisation. This will allow quicker and better support to biomarker testing, allowing earlier treatment with the most appropriate drug treatment sooner.

Test Signal was previously available as a monthly report. However, with the additional investment Diaceutics' has made, Test Signal alert is now available as a real time report further enhancing the DXRX Diaceutics Commercialisation Platform. This service now adds to the comprehensive suite of modules now being offered by Diaceutics, on a subscription basis. Work is now nearing completion for additional modules that will join Test Signal on the DXRX Commercialisation Platform.

Test Signal was trialed prior to launch with key Pharma clients from the beginning of November 2021 and the Company is delighted to report that it has already secured six multiyear data subscriptions for the service. This opens up a new revenue stream for Diaceutics which will be added to as the Commercialisation Platform matures, underpinning the Company's confidence in achieving sustained long-term growth.

Peter Keeling, CEO and Founder of Diaceutics, commented:

"The launch of Test Signal represents another big step on our journey towards platformisation of our business model and delivery of recurring, high margin and scalable multi year subscription revenues. The provision of this sophisticated real time patient testing data has been made possible by our investments in DXRX. Test Signal supports our Pharma clients and their physicians by identifying patient cohorts eligible for treatment sooner than is currently practicable and where treatment can be more effective, a key goal for all involved in precision medicine. We have been delighted by the swift adoption of the service by both existing and new pharma customers."

Enquiries:

Diaceutics PLC

Philip White, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison, Stewart Wallace, Nick Adams

Tel: +44 (0)20 7710 7600

Alma PR

Caroline Forde, Kieran Breheny, Matthew Young

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUWARRANUURUA